Pearl Therapeutics co-suspension formulation technology wins US patent

The Patent No. 8,324,266 covers methods for treating pulmonary disease using Pearl’s co-suspension technology in metered-dose inhalers (MDIs).

The technology is used in PT003, a fixed dose combination of glycopyrrolate (GP) and formoterol fumarate (FF), as well as PT010, a triple-combination of GP, FF and an inhaled corticosteroid.

Pearl Therapeutics chief executive officer Chuck Bramlage said the patency period until 2030 provides the company with control for the long-term commercial value of its combination product portfolio, including PT003.

"This patent marks the rapid evolution of Pearl’s intellectual property beyond the patent portfolio in-licensed in 2007," Bramlage added.

"With the recent completion of PT003’s Phase 2 program, we are preparing to advance it into Phase 3 in 2013, and subsequently to bring to market this valuable therapy for the millions of individuals whose COPD is inadequately controlled with current medications," Bramlage added.